



Please amend the claims (10/064,698, Confirmation No. 9324, art unit 1615) as follow and consider our remarks. Please note that Claims 7 through 20 and claim 24 have been cancelled rather than withdrawn according to your suggestion.

1- (Amended) Method for enhancing hair growth in mammals, comprising administering topically to the skin a mixture of a nitric oxide (NO) donor such as minoxidil, or 6-(1-piperidiny)pyrimidine-2,4-diamine 3-oxide and a cyclic guanosine 3',5'-monophosphate (cGMP) specific phosphodiesterase type 5 (PDE5) inhibitor such as sildenafil citrate ( $C_{22}H_{30}N_6O_4S \cdot C_6H_8O_7$ ) in a dermatologically acceptable solution mix.

2- (Original) Method according to claim 1, wherein said topical dermatological compound is in the form of an aqueous solution or suspension, or in the form a gel, a shampoo, an ointment or a cream in a pharmaceutically acceptable dermatological vehicle or carrier to be applied to the mammalian skin.

3- (Amended) Method according to claim 1, wherein the Nitric Oxide (No) releasing agent in said dermatological mix is glyceryl trinitrate or nitroglycerine ( $C_3H_5N_3O_9$ )

4- (Amended) Method according to claim 1, wherein the Nitric Oxide (No) releasing agent in said dermatological mix is L-arginine or ( $C_6H_{14}N_4O_2$ ).

5- (Amended) Method according to claim 1, wherein the Nitric Oxide (No) releasing agent in said dermatological mix is a isosorbide dinitrate or ( $C_6H_8N_2O_8$ )

6- (Amended) Method according to claim 1, wherein the Nitric Oxide (No) releasing agent in said dermatological mix is nitroprusside or ( $Na_2Fe(CN)_5NO \cdot 2H_2O$ )

Claims 7 through 20 and 24 are considered cancelled.

21- (Original) The composition according to claim 1, wherein said dose is in pill form for oral administration.

22- (Original) The method according to claim 1, wherein said topical dermatological mix further contains one or more combinations of NO donors and cGMP PDE5 inhibitors.

23- (Original) The method according to claim 1, wherein said topical dermatological mix further contains one or more weight or volume percentage combinations of NO donors and cGMP PDE5 inhibitors.

25- (Original) A composition according to claim 1 used in veterinary preparations or feeds to increase the rate of growth of fur (pelt) in certain fur bearing animals and to retard shedding and molting.



Thus the new set of claims is:

1- Method for enhancing hair growth in mammals, comprising administering topically to the skin a mixture of a nitric oxide (NO) donor such as minoxidil, or 6-(1-piperidinyl)pyrimidine-2,4-diamine 3-oxide and a cyclic guanosine 3',5'-monophosphate (cGMP) specific phosphodiesterase type 5 (PDE5) inhibitor such as sildenafil citrate ( $C_{22}H_{30}N_6O_4S \cdot C_6H_8O_7$ ) in a dermatologically acceptable solution mix.

2- Method according to claim 1, wherein said topical dermatological compound is in the form of an aqueous solution or suspension, or in the form a gel, a shampoo, an ointment or a cream in a pharmaceutically acceptable dermatological vehicle or carrier to be applied to the mammalian skin.

3- Method according to claim 1, wherein the No releasing agent in said dermatological mix is glyceryl trinitrate or nitroglycerine ( $C_3H_5N_3O_9$ )

4- Method according to claim 1, wherein the No releasing agent in said dermatological mix is L-arginine or ( $C_6H_{14}N_4O_2$ ).

5- Method according to claim 1, wherein the No releasing agent in said dermatological mix is a isosorbide dinitrate or ( $C_6H_8N_2O_8$ )

6- Method according to claim 1, wherein the No releasing agent in said dermatological mix is nitroprusside or ( $Na_2Fe(CN)_5NO \cdot 2H_2O$ )

7-The composition according to claim 1, wherein said dose is in pill form for oral administration.

8-The method according to claim 1, wherein said topical dermatological mix further contains one or more combinations of NO donors and cGMP PDE5 inhibitors.

9-The method according to claim 1, wherein said topical dermatological mix further contains one or more weight or volume percentage combinations of NO donors and cGMP PDE5 inhibitors.

10- A composition according to claim 1 used in veterinary preparations or feeds to increase the rate of growth of fur (pelt) in certain fur bearing animals and to retard shedding and molting.

These claims have been revised and amended or cancelled based on the Examiners' election/restrictions under 35 USC 103, 35 USC 112.